

# Benralizumab (Fasenra®)

---

## Selected References

- Agache I, et al. 2020. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. *Allergy*. 75(5):1023-1042.
- Manetz S, et al. 2020. Successful pregnancy in setting of eosinophil depletion by benralizumab. *J Allergy Clin Immunol Pract*. S2213-2198(20)31335-0.
- Middleton PG, et al. 2020. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. *Eur Respir J*. 55:1901208.
- National Center for Biotechnology Information. “PubChem Compound Summary for , Benralizumab” PubChem, Accessed 7 Oct 2024.
- S. Food and Drug Administration. 2024. Fasenra® Prescribing Information. Available online at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/761070s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf). Accessed on 9 Dec 2024.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, December 1, 2024.

---

# Benralizumab (Fasenra®)

---

## Selected References:

- Anh, N., et al. 2020. Ginger on Human Health: A Comprehensive Systematic Review of 109 randomized Controlled Trials. *Nutrients*. 6:12(1):157.
- Briggs GG, Freeman RK. 2014. The reference guide to fetal and neonatal risk: Drugs in pregnancy and lactation. Wolters Kluwer, PA: Wolters Kluwer Health.
- Choi JS, et al. 2015. Assessment of fetal and neonatal outcomes in the offspring of women who had been

treated with dried ginger (*Zingiberis rhizome siccus*) for a variety of illnesses during pregnancy. *J Obstet Gynaecol.* 35(2): 125-130.

- Fischer-Rasmussen, et al. 1991. Ginger treatment of hyperemesis gravidarum. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 38(1):19-24.
- Heitmann K, et al. 2013. Safety of ginger use in pregnancy: results from a large population-based cohort study. *Eur J Clin Pharmacol.* 69(2):269-77.
- Laekeman GM, et al. 2021 Ginger (*Zingiber officinale*) Root Extract During Pregnancy: A Clinical Feasibility Study. *Planta Med.* 87(10-11):907-912.
- Matthews, A, et al. 2014. Interventions for nausea and vomiting in early pregnancy. *Cochrane Database Syst Rev*, 3.
- McLay JS, et al. 2017. Pregnancy, prescription medicines and the potential risk for herb-drug interactions: a cross-sectional survey. *BMC Complement Altern Med* 17(1):543.
- Shalaby MA and Hamowieh AR. 2010. Safety and efficacy of *Zingiber officinale* roots on fertility of male diabetic rats. *Food Chem Toxicol.* 48(10):2920-4.
- Tiani K, et al. 2024. The Use of Ginger Bioactive Compounds in Pregnancy: An Evidence Scan and Umbrella Review of Existing Meta-Analyses. *Advances in Nutrition*, 15(11), 100308
- Tiran D. 2012. Ginger to reduce nausea and vomiting during pregnancy: evidence of effectiveness is not the same as proof of safety. *Complement Ther Clin Pract.* 2012 Feb;18(1):22-5.
- Viljoen, E., et. al. 2014. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. *Nutr J.* 13(20):1-14.
- Weidner, M. S., and Sigwart, K. 2000. Investigation of the teratogenic potential of a *Zingiber officinale* extract in the rat. *Reproductive Toxicology*, 15(1):75-80.

**Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).**

---

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, December 1, 2024.

---

# Benralizumab (Fasenra®)

## Selected References:

- Allotey J, et al. 2020. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ* 370:m3320.
- American Society of Hematology. 2022. COVID-19 and VTE/anticoagulation: frequently asked questions. Available at URL: <https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation>
- Angelidou A, et al. 2021. Association of maternal perinatal SARS-CoV-2 infection with neonatal outcomes during the COVID-19 pandemic in Massachusetts. *JAMA Netw Open* Apr 1;4(4):e217523.
- Auger N, et al. Congenital anomalies during Covid-19: artifact of surveillance or a real TORCH? *Eur J Epidemiol*. 39(6):613-621.
- Carlson J, et al. Pre-Delta, Delta, and Omicron periods of the Coronavirus Disease 2019 (COVID-19) pandemic and health outcomes during delivery hospitalization. *Obstet Gynecol*. 143(1):131-138.
- Chambers, et al. 2020. Evaluation for SARS-CoV-2 in breast milk from 18 infected women. *JAMA* 324(13):1347-1348.
- Che BW, et al. Effects of mild/asymptomatic COVID-19 on semen parameters and sex-related hormone levels in men: a systematic review and meta-analysis. *Asian J Androl*. 25(3):382-388.
- Chen H, et al. 2020. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet* 395(10226):809-815.
- Delahoy MJ, et al. 2020. Characteristics and maternal and birth outcomes of hospitalized pregnant women with laboratory-confirmed COVID-19 — COVID-NET, 13 states, March 1–August 22, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1347–1354.
- DeSisto C, et al. 2021. Risk for stillbirth among women with and without COVID-19 at delivery hospitalization – United States, March 2020–September 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:1640–1645.
- Edlow AG, et al. 2022. Neurodevelopmental outcomes at 1 year in infants of mothers who tested positive for SARS-CoV-2 during pregnancy. *JAMA Netw Open* 5(6):e2215787.
- Edlow AG, et al. 2023. Sex-specific neurodevelopmental outcomes among offspring of mothers with SARS-CoV-2 infection during pregnancy. *JAMA Netw Open*. 1;6(3):e234415.
- Ellington S, et al. 2020. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status — United States, January 22–June 7, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:769–775.
- Engjom HM, et al. 2024. Perinatal outcomes after admission with COVID-19 in pregnancy: a UK national cohort study. *Nat Commun*. 15;15(1):3234.
- Fajardo-Martinez V, et al. 2024. Neurodevelopmental delay in children exposed to maternal SARS-CoV-2 in-utero. *Sci Rep*. 24;14(1):11851.
- Firestein MR, et al. 2023. Assessment of neurodevelopment in infants with and without exposure to asymptomatic or mild maternal SARS-CoV-2 infection during pregnancy. *JAMA Netw Open*. 6(4):e237396.
- Galang RR, et al. 2021. Risk factors for illness severity among pregnant women with confirmed SARS-CoV-2 infection – Surveillance for Emerging Threats to Mothers and Babies Network, 22 state, local, and territorial health departments, March 29, 2020 –March 5, 2021. *Clin Infect Dis* May 22:ciab432.
- Gilbert G.G. et al. 2021. Sperm quality and absence of SARS-CoV-2 RNA in semen after COVID-19 infection: a prospective, observational study and validation of the SpermCOVID test. *Fertility and Sterility* 117(2):287-296.
- Gulersen M, et al. 2020. Clinical implications of SARS-CoV-2 infection in the viable preterm period. *Am J Perinatol* 37(11): 1077-1083.
- Gurol-Urganci I, et al. 2021. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study. *Am J Obstet Gynecol* May 20:S0002-9378(21)00565-2.
- Harel L, et al. 2021. Does the presence of symptoms affect pregnancy outcomes in third trimester in women

with SARS-CoV-2. *The Journal of Maternal-Fetal & Neonatal Medicine*. 35(25):7582–7589.

- Hernández-Díaz S, et al. 2022. First trimester COVID-19 and the risk of major congenital malformations–international registry of coronavirus exposure in pregnancy. *Birth Defects Res* 1;114(15):906-914.
- Holtmann N, et al. 2020. Assessment of SARS-CoV-2 in human semen – a cohort study. *Fertility and Sterility* 114 (2):233-238.
- Huynh A, et al. 2022. SARS-CoV-2 placentitis and intraparenchymal thrombohematomas among COVID-19 infections in pregnancy. *JAMA Netw Open* 5(3):e225345.
- Jaswa EG, et al. 2024. In utero exposure to maternal COVID-19 and offspring neurodevelopment through age 24 months. *JAMA Netw Open*. 7(10):e2439792.
- Jering K, et al. 2021. Clinical characteristics and outcomes of hospitalized women giving birth with and without COVID-19. *JAMA Intern Med* 181(5):714-717.
- Karasek D, et al. 2021. The association of COVID-19 infection in pregnancy with preterm birth: A retrospective cohort study in California. *The Lancet Regional Health – Americas Volume 2*. DOI: <https://doi.org/10.1016/j.lana.2021.100027>
- Khoury R, et al. 2020. **MD** Characteristics and outcomes of 241 births to women with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at five New York City medical centers. *Obstetrics & Gynecology* 136(2):273-282.
- Krogstad P, et al. 2022. No infectious SARS-CoV-2 in breast milk from a cohort of 110 lactating women. *Pediatr Res*. Published online January 19, 2022. DOI: <https://doi.org/10.1038/s41390-021-01902-y>
- Kummer J, et al. 2024. Covid-19 during pregnancy – Histopathological lesions of the placenta. *Z Geburtshilfe Neonatol*. 228(1):49-56.
- Lai J, et al. 2021. SARS-CoV-2 and the subsequent development of preeclampsia and preterm birth: evidence of a dose-response relationship supporting causality. *AJOG* 225(6):689-693.e1.
- Lau M, 2023. Observational study on the neonatal outcome during the COVID-19 pandemic in Germany. *Acta Paediatr*. 112(9):1892-1897.
- Li Y, et al. 2020. Lack of vertical transmission of severe acute respiratory syndrome coronavirus 2, China. *Emerg Infect Dis* 26(6):1335-1336.
- Ludvigsson JF, et al. 2024. Three Scandinavian countries did not see the same increase in foetal situs inversus observed in China during the COVID-19 pandemic. *Acta Paediatr*. 113(4):751-752.
- Maeda MFY, et al. 2021. Vertical transmission of SARS-CoV2 during pregnancy: a high-risk cohort. *Prenat Diag Jul*;41(8):998-1008.
- Magnus MC, et al. 2024. Covid-19 infection and vaccination during first trimester and risk of congenital anomalies: Nordic registry based study. *BMJ*. 386:e079364.
- Metz TD, et al. 2022. Association of SARS-CoV-2 infection with serious maternal morbidity and mortality from obstetric complications. *JAMA* 327(8):748-759.
- Neelam V, et al. 2022. Pregnancy and infant outcomes by trimester of SARS-CoV-2 infection in pregnancy – SET-NET, 22 jurisdictions, January 25, 2020 - December 31, 2020. *Birth Defects Research*, 1– 15.
- Newton SM, et al. Preterm birth among pregnant persons with severe acute respiratory syndrome Coronavirus 2 infection. *J Perinatol* 42:1328–1337.
- Norman M, et al. 2021. Association of maternal SARS-CoV-2 infection in pregnancy with neonatal outcomes. *JAMA* May 25;325(20):2076-2086.
- Piekos SN, et al. 2022. The effect of maternal SARS-CoV-2 infection timing on birth outcomes: a retrospective multicentre cohort study. *Lancet* 4(2):E95-E104.
- Reeves EL, et al. 2024. Pregnancy and infant outcomes following SARS-CoV-2 infection in pregnancy during delta variant predominance – Surveillance for Emerging Threats to Pregnant People and Infants. *Am J Obstet Gynecol MFM*. 6(2):101265.
- Ren H, et al. 2024. The association of increased incidence of congenital heart disease in newborns with maternal COVID-19 infection during pregnancy. *Sci Rep*. 22;14(1):24866.

- Rosen H, et al. 2021. Fetal and perinatal outcome following first and second trimester COVID-19 infection: evidence from a prospective cohort study. *J Clin Med* May 16;10(10):2152.
- Salvatore CM, et al. 2020. Neonatal management and outcomes during the COVID-19 pandemic: an observation cohort study. *Lancet Child & Adol Health* 4(10):721-727.
- Santos CAD, et al. 2024. Developmental impairment in children exposed during pregnancy to maternal SARS-CoV-2: A Brazilian cohort study. *Int J Infect Dis.* 139:146-152.
- Sardinha TG, et al. 2024. The effect of body mass index on maternal and perinatal outcomes in COVID-19 infection during pregnancy and postpartum: Secondary analysis from the REBRACO cohort study. *Int J Gynaecol Obstet.* 164(3):1019-1027.
- Scalia B, et al. 2024. Cranial ultrasonographic findings in newborns exposed to SARS-CoV-2: a single-centre cross-sectional analysis. *Ital J Pediatr.* 5;50(1):257.
- Schulte A, et al. 2024. COVID-19 in pregnancy: prevalence, management, and outcomes in a single large health system. *J Matern Fetal Neonatal Med.* 37(1):2409360.
- Shlomai NO, et al. 2021. Neonatal SARS-CoV-2 infections in breastfeeding mothers. *Pediatrics* May;147(5):e2020010918.
- Shuffrey LC, et al. 2021. Association of birth during the COVID-19 pandemic with neurodevelopmental status at 6 months in infants with and without in utero exposure to maternal SARS-CoV-2 infection. *JAMA Pediatr* 176(6):e215563.
- Smith ER, et al. 2023. Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection: an individual participant data meta-analysis. *BMJ Glob Health* 8(1):e009495.
- Stock S, et al. 2022. SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland. *Nat Med* 28, 504-512.
- van Baar JAC, et al: PregCOV-19 Living Systematic Review Consortium. 2024. COVID-19 in pregnant women: a systematic review and meta-analysis on the risk and prevalence of pregnancy loss. *Hum Reprod Update.* 1;30(2):133-152.
- Villar J, et al. 2021. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. *JAMA Pediatr* Apr 22:e211050.
- Vivanti AJ, et al. 2020. Transplacental transmission of SARS-CoV-2 infection. *Nat Commun* 11,
- Wei SQ, et al. 2021. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. *CMAJ* Apr 19;193(16):E540-E548.
- Wang Y, et al. 2023. Association of SARS-CoV-2 infection during early weeks of gestation with situs inversus. *N Engl J Med.* 2;389(18):1722-1724.
- Wesselink A, et al. 2022. A prospective cohort study of COVID-19 vaccination, SARS-CoV-2 infection, and fertility. *American Journal of Epidemiology* 191(8):1383-1395.
- Wong YP, et al. 2021. The effects of COVID-19 on placenta and pregnancy: what do we know so far? *Diagnostics (Basel)* Jan 8;11(1):94.
- Zambrano LD, et al. 2020. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status — United States, January 22–October 3, 2020. *MMWR Morb Mortal Wkly Rep* 69:769–75.
- Zeng L, et al. 2020. Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. *JAMA Pediatr* 174(7):722-725.
- Zhou SM, et al. 2024. COVID-19 and pregnancy: a comprehensive study of comorbidities and outcomes. *BMC Public Health.* 24(1):3157.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, December 1, 2024.

## Benralizumab (Fasenra®)

### Selected References:

- Abernathy A, et al. 2017. Transient fetal tachycardia after intravenous diphenhydramine administration. *Obstet* 130(2):374-376.
- Aldridge T, et al. 2014. First-trimester antihistamine exposure and risk of spontaneous abortion or preterm birth. *Pharmacoepidemiol Drug Saf*. Oct 23 (10):1043-50.
- Anderka M, et al, and the National Birth Defects Prevention Study. 2012. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. *Birth Defects Res (Part A)* 94:22-30.
- Aselton P, et al. 1985. First-trimester drug use and congenital disorders. *Obstet Gynecol* 65(4):451-455.
- Brost BC, et al. 1996. Diphenhydramine overdose during pregnancy: Lessons from the past. *Am J Obstet Gynecol* 175:1376-7.
- Black RA, et al. 2003. Over-the-Counter Medications in Pregnancy. *Am Fam* 67(12):2517-2524.
- Brzezińska-Wcisło L, et al. 2017. Pregnancy: a therapeutic dilemma. *Adv Dermatol Allergol*:XXXIV (5): 433-438.
- Chaudhry SK & Susser LC. 2018. Considerations in treating insomnia during pregnancy: a literature review. *Psychosomatics*, 59(4), 341-348.
- Cohen F, et al. 2021. A randomized study of IV prochlorperazine plus diphenhydramine versus IV hydromorphone for migraine-associated symptoms: A post hoc analysis. *Headache*. 61(8):1227-1233.
- Friedman BW, et al. 2016. Diphenhydramine as Adjuvant Therapy for Acute Migraine: An Emergency Department-Based Randomized Clinical Trial. *Ann Emerg Med*. 67(1):32-39.
- Gilboa SM, et al. 2009. National Birth Defects Prevention Study: Use of antihistamine medications during early pregnancy and isolated major malformations. *Birth Defects Res A Clin Mol Teratol* 85(2):137-150.
- Hansen C, et al. 2020. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997–2011. *Birth Defects Research*, 112(16), 1234-1252.
- Hara GS, et al. 1980. Dramamine in labor: potential boon or a possible bomb? *J Kans Med Soc* 81(3):134-136, 155.
- Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. *Am J Obstet Gynecol* 168:1393-9.
- Kargas GA, et al. 1985. Perinatal mortality due to interaction of diphenhydramine and temazepam. *N Eng J Med* 313:1417-8.
- Li Q, et al. 2013. Assessment of antihistamine use in early pregnancy and birth defects. *J Allergy Clin Immunol Pract*. 1(6):666-e1.
- McLafferty LP, et al. 2018. Pharmacologic treatment of sleep disorders in Sleep medicine clinics, 13(2), 243-250.
- Miller MA, et al. 2020. Sleep pharmacotherapy for common sleep disorders in pregnancy and lactation. *Chest*, 157(1), 184-197.
- Moraes AP, et al. 2004. Maternal exposure to diphenhydramine during the fetal period in rats: effects on

physical and neurobehavioral development and on neurochemical parameters. *Neurotoxicol Teratol* 26(5):681-692.

- Moretti ME, et al. 1995. Adverse events in breastfed infants exposed to antihistamines in maternal milk. *Reprod Toxicol* 9: 588.
- O'Brien TE. 1974. Excretion of drugs in human milk. *Am J Hosp Pharm* 31:844-54.
- Parken DE. 1974. Probably Benadryl withdrawal manifestations in a newborn infant. *J Pediatr* 85:580.
- Saldanha IJ, et al. 2021. Management of primary headaches during pregnancy, postpartum, and breastfeeding: A systematic review. *Headache*, 61(1):11-43.
- Saxen I. 1974. Cleft palate and maternal diphenhydramine intake. *Lancet* 1(7854):407-408.
- Shenai N, et al. 2018. Fetal outcomes in intentional over-the-counter medication overdoses in *Psychosomatics* 4:400-404.
- So M, et al. 2010. Safety of antihistamines during pregnancy and lactation. *Can Fam Physician* 56(5):427-429.
- Spencer JP, et al. 2001. Medications in the Breast-feeding Mother. *Am Fam Physician* 64(1): 119-127.
- Wolfson AR, et al. 2022. Diphenhydramine: Time to Move on? *J Allergy Clin Immunol Pract*. 10(12):3124-313.

**Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).**

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, December 1, 2024.

---

## Benralizumab (Fasenra®)

---

### Selected References:

- Andersen JT, et al. 2014. Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage. *Obstet Gynecol* 124: 655-661.
- Anderson KN, et al. 2020. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. *JAMA Psychiatry*. 77(12):1246-1255
- Bérard A, et al. 2017. SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn. *Br J Clin Pharmacol*. 83(5):1126-1133.

- Berle JO, et al. 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. *J Clin Psychiatry*. 65:1228-1234.
- Bonari L, et al. 2004. Perinatal risks of untreated depression during pregnancy. *Can J Psychiatry* 49(11):726-
- Chambers CD, et al. 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med* 354:579-587.
- Colvin L, et al. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. *Birth Defects Research Part A: Clinical and Molecular Teratology* 91:142-152
- Cornet MC, et al. Maternal treatment with selective serotonin reuptake inhibitors during pregnancy and delayed neonatal adaptation: a population-based cohort study. *Arch Dis Child Fetal Neonatal Ed* 18;109(3):294-300.
- Den Besten-Bertholee D, et al. Sertraline, citalopram and paroxetine in lactation: passage into breastmilk and infant exposure. *Front Pharmacol* 22(15):1414677.
- Desaunay P, et al. 2024. Antidepressants and fetal death: A systematic review and disproportionality analysis in the WHO safety database (VigiBase®). *Psychiatry Res* 339:
- Einarson A, et al. 2009. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. *Can J Psychiatry* 54(4):242-246.
- Ericson A, et al. 1999. Delivery outcome after the use of antidepressants in early pregnancy. *Eur J Clin Pharmacol* 55:503-508.
- Gao SY, et al. 2018. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. *BMC Med* 16(1):205.
- Gram MA, et al. Antidepressant exposure patterns during pregnancy and risk of adverse newborn outcomes. *Psychiatry Res* 342:116274.
- Grigoriadis S, et al. 2013. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. *J Clin Psychiatry*.74(4):e309-20.
- Heikkinen T, et al. 2002. Citalopram in pregnancy and lactation. *Clin Pharmacol Ther* 72:184-191.
- Jimenez-Solem E, et al. 2012. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. *BMJ Open*:2e001148 doi:10.1136/bmjopen-2012-001148.
- Jordan AE, et al. 2008. Serotonin reuptake inhibitor use in pregnancy and the neonatal behavioral syndrome. *J Matern Fetal Neonatal Med* 21(10):745-751.
- Huybrechts KF, et al. 2014. Antidepressant use in pregnancy and the risk of cardiac defects. *N Engl J Med*. 370(25):2397-407.
- Kallen BAJ and Otterblad Olausson P. 2007. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. *Birth Defects Res A Clin Mol Teratol* 79(4):301-308.
- Kallen B and Otterblad Olausson P. 2008. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. *Pharmacoepidemiol Drug Saf* 17:801-806.
- Kieler H, et al. 2012. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic BMJ; 344:d8012.
- Kieviet N, et al. 2015. Risk factors for poor neonatal adaptation after exposure to antidepressants in utero. *Acta Paediatr*. 104(4):384-91.
- Louik C, et al. 2007. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. *N Engl J Med* 356:2675-2683.
- Milosavljević JZ, et al. 2022. The effects of selective serotonin reuptake inhibitors on male and female fertility: a brief literature review. *Int J Psychiatry Clin Pract*. 26(1):43-49.
- Morales DR, et al. Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations. *BMC Med*. 16:1-14.
- Moses-Kolko, EL, et al. 2005. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications. *JAMA* 293:2372-2383.
- Newport DJ, et al. 2002. The treatment of postpartum depression: Minimizing infant exposure. *J Clin Psychiatry*

63(Suppl 7): 31-44.

- Rampono J, et al. 2006. Transfer of escitalopram and its metabolite demethylescitalopram into breastmilk. Br J Clin Pharmacol 3:316-22.
- Reefhuis J, et al. 2015. Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous Bmj. 351:h3190.
- Reis M and Kallen B. 2010. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 40(10):1723-1733.
- Sivojelezova A, et al. 2005. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 193:2004-9.
- Sjaarda LA, et al. Urinary selective serotonin reuptake inhibitors across critical windows of pregnancy establishment: A prospective cohort study of fecundability and pregnancy loss. Fertil Steril 114:1278-1287.
- Tabacova SA, et al. 2004. Adverse developmental events reported to FDS in association with maternal citalopram treatment in Birth Defects Res 70:361.
- Wang S, et al. 2015. Selective serotonin reuptake inhibitors (SSRIs) and the risk of congenital heart defects: A meta-analysis of prospective cohort studies. Journal of the American Heart Association. 4(5).
- Weissman AM, et al. 2004. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 161:1066-1078.

**Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).**

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, December 1, 2024.